Expert Opinion on Drug Metabolism & Toxicology

Papers
(The TQCC of Expert Opinion on Drug Metabolism & Toxicology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
Probing the mechanism of reduced in vivo potency of insulin detemir121
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects116
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata70
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine64
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria31
Hormones, microbes, and PrEP drugs in the female genital tract29
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury29
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury27
Comorbidities and the right dose: antipsychotics26
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis26
Pharmacotherapy in kidney disease: what it takes to move from general guidance to specific recommendations to stratified subgroups of patients - the tale of autosomal dominant polycystic kidney diseas23
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update23
Guidance for interactions between antiseizure medications22
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database22
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis20
In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals19
Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease19
Correction18
Bioactivity descriptors for in vivo toxicity prediction: now and the future18
A comprehensive review of the efficacy and safety of ertugliflozin17
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update17
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer17
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study17
Pharmacokinetic evaluation of concizumab for the treatment of hemophilia16
Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase16
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury16
A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition15
Clinical pharmacokinetics and pharmacodynamics of nicardipine; a systematic review15
Drug-drug interactions between psychotropic medications and oral contraceptives14
A high-throughput liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of p -cresol sulfate, p -cresol14
Pharmacokinetic considerations surrounding triple therapy for uncontrolled asthma14
Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen13
Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase13
Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders13
Physiologically based pharmacokinetic modeling in obesity: applications and challenges12
Risk factors and prediction for DILI in clinical practice12
Development and hepatotoxicity of rifamycin derivatives12
Population pharmacokinetic–pharmacodynamic analysis of givinostat12
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care – an overview12
Evaluating pharmacokinetic drug–drug interactions of direct oral anticoagulants in patients with renal dysfunction11
Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation11
The impact of advanced age on anticoagulant therapy for acute venous thromboembolism11
Drug absorption from oral formulations in patients with short bowel syndrome: a comprehensive update of the literature11
Current state-of-the-art approaches for mass spectrometry in clinical toxicology: an overview11
Recent progress in machine learning approaches for predicting carcinogenicity in drug development11
Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies10
The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity – a review of pharmacological and clinical data10
Integrative approaches for studying the role of noncoding RNAs in influencing drug efficacy and toxicity10
In-silico approaches to assessing multiple high-level drug-drug and drug-disease adverse drug effects10
Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review10
Antisense oligonucleotides: absorption, distribution, metabolism, and excretion9
Practical perspectives on addressing hepatotoxicity during clinical candidate selection9
Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjec9
Interactions between phytotherapeutics and chemotherapeutics: the current evidence9
Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction9
PBPK models of the female reproductive tract: current and future analysis9
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes9
An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease9
CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study8
Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature8
Cardiomyocyte-specific CYP2J2 and its therapeutic implications8
Development and application of a population pharmacokinetic model repository for caffeine dose tailoring in preterm infants8
Analysis of drug–drug interactions in patients with HIV and metabolic syndrome8
Switching from cangrelor to oral P2Y 12 inhibitors: a focused review on drug–drug interactions8
Bioequivalence of generic and branded ibrutinib capsules in healthy Chinese volunteers under fasting and fed conditions: a randomized, four-period, fully replicated, crossover study8
Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling8
Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson’s disease7
Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults7
Machine learning and deep learning approaches for enhanced prediction of hERG blockade: a comprehensive QSAR modeling study7
Overcoming barriers to machine learning applications in toxicity prediction7
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis7
Positioning the new drugs for migraine7
Drug interactions in people with HIV treated with antivirals for other viral illnesses7
Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications7
Safety of concomitant use of oral anticoagulants and antidiabetic drugs: a systematic review of observational studies7
The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications7
Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers7
Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healt7
Pharmacokinetic and pharmacodynamic alterations in older people: what we know so far7
Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention7
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine6
Regulation of cyclophosphamide induced hepatotoxicity by REV-ERBα modifiers6
Toxic metabolites and metabolic soft spots of celastrol based on glutathione metabolic capture and high-resolution mass spectrometry6
Considerations for drug–drug interactions between long-acting antiretrovirals and immunosuppressants for solid organ transplantation6
Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability6
The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review6
Managing intoxications with nicotine-containing e-liquids6
Drug dosing optimization in critically ill children under continuous renal replacement therapy: from basic concepts to the bedside model informed precision dosing6
The role of pharmacogenetics in the treatment of anxiety disorders and the future potential for targeted therapeutics6
Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism: the consequences on mitochondrial dysfunction and oxi6
Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids6
Mechanism-based drug safety testing using innovative in vitro liver models: from DILI prediction to idiosyncratic DILI liability assessment6
0.04448413848877